Loading clinical trials...
Loading clinical trials...
Effect of 3 Consecutives Botulinum Toxin Injection on Gait Pattern in Stroke Patients
Chronic stroke patients exhibit gait pattern alterations which are mainly due to spasticity and treated with repetitive multifocal botulinum toxin injection(BTI). Several studies demonstrated that single BTI-session in a single muscle of paretic lower limb(LL) improved kinematic gait parameters(GP) but surprisingly none of them assessed the effects of repetitive multifocal BTI on patient's gait pattern and their duration. The aim was to evaluate the impact of repetitive multifocal BTI-sessions on GP of chronic stroke patients. To that end, gait of patients will be compared using 3D-gait analysis after 3 consecutives BTI sessions.
All the patients will be treated with BTI . These injections will be performed under electrical stimulation control (\~5mA). The dose, the number of site of injection per muscle is at the discretion of the physician according to patients' needs and physicians' routine clinical practice. The dilution the most commonly used will be 100 U for 2.5ml (XEOMIN®)
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Raymond Poincaré hospital
Garches, France
Start Date
December 12, 2017
Primary Completion Date
October 1, 2019
Completion Date
December 1, 2019
Last Updated
January 25, 2018
30
ESTIMATED participants
Motion Analysis
OTHER
Lead Sponsor
Centre d'Investigation Clinique et Technologique 805
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions